A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Table 4 Response in measurable lesions

Groups	N	PR	SD	PD	ORR (%)	DCR (%)	P value*
All patients	45	14	22	9	31.8	77.3	0.54
No ascites	28	11	14	3	39.2	89.2
Small to moderate ascites	12	2	6	4	16.7	66.7
Massive ascites	5	1	2	2	20.0	60.0

CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate (CR + PR + SD)
*Comparison of ORR between 3 groups

ISSN: 1471-2407